When symptoms persist: Choosing among alternative somatic treatments for schizophrenia

Schizophrenia Bulletin

Volumn 17, Issue 2, 1991, Pages 217-245

  Christison, George W ^a   Kirch, Darrell G ^b   Wyatt, Richard Jed ^c  

^a LOMA LINDA UNIVERSITY HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c Intramural Res Prog Natl I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; APOMORPHINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ENDORPHIN; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLECYSTOKININ; CLONIDINE; CLOPENTHIXOL; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LEVODOPA; LITHIUM; NALOXONE; NALTREXONE; NEUROLEPTIC AGENT; PLACEBO; PROPRANOLOL; RESERPINE; TRIFLUOPERAZINE; VALPROIC ACID; VASOPRESSIN; VERAPAMIL;

ATAXIA; DROWSINESS; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERSALIVATION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEIZURE;

ANTI-ANXIETY AGENTS, BENZODIAZEPINE; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; CLOZAPINE; DOUBLE-BLIND METHOD; ELECTROCONVULSIVE THERAPY; HUMAN; LEVODOPA; LITHIUM; PROPRANOLOL; RESERPINE; SCHIZOPHRENIA;

EID: 0025938251     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/schbul/17.2.217     Document Type: Article

References (0)